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Background: Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which
have a major negative impact on social function and objective quality of life. Standard drug treatments have little
impact on either. There is some evidence that anti-inflammatory treatment may have beneficial effects in
schizophrenia and major depression. Statins are cholesterol-lowering agents that have been found to be anti-
inflammatory agents and are also known to decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3)
receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer.
Small studies have suggested that ondansetron is effective as an adjunct drug in improving the symptoms of
schizophrenia.
Methods/design: This is a two center, six-month, double-blind placebo controlled, factorial design study of
ondansetron and/or simvastatin added to treatment as usual for patients suffering from schizophrenia,
schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. This will be a 2 × 2 design,
with 54 patients in each cell, giving a total of 216 patients over three years. There will be a screening, a
randomization and seven follow-up visits. Full clinical and neurocognitive assessments will be carried out at
baseline (randomization), 14 weeks and at 26 weeks, while the positive and negative syndrome scale (PANSS), pill
count and side effects checklist will be carried out at every visit. Simvastatin will be started at 20 mg once daily
(OD), this will be increased to 40 mg after four weeks. Ondansetron will be administered in an 8 mg dose.
Discussion: Anti-inflammatory treatments have been shown to have some beneficial effects in schizophrenia. Both
simvastatin and ondansetron provide some evidence of a reduction in symptoms compared to treatment as usual.
The aim of this study is to establish the degree of improvement in negative symptoms with the addition of
ondansetron and/or simvastatin to treatment as usual.
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Table 1 2 × 2 Factorial design
Placebo Simvastatin Total
Placebo 54 54 108
Ondansetron 54 54 108
Total 108 108
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Although dopamine remains the primary neurotransmitter
implicated in pathogenesis of schizophrenia, there is grow-
ing evidence to support inflammatory processes to be in-
volved as well [1]. A number of studies have reported
increased peripheral inflammatory cytokines (interleukin-1
(IL-1), IL-2, IL-6, and tumor necrosis factor alpha) [2] and
elevated IL-1 in cerebrospinal fluid (CSF) of patients with
schizophrenia [3]. In the brain, cytokines seem to be in-
volved in regulating the action of several neurotransmitters,
such as serotonin, noradrenaline, dopamine and glutamate.
The interaction of cytokines with dopamine and glutamate
seems to be especially relevant to the pathophysiology of
schizophrenia [4].
Currently available treatments for schizophrenia are
effective in treating positive symptoms, but have little or
no impact on primary negative symptoms [5]. Negative
symptoms and cognitive deficits are two partially-related
features of schizophrenia which have a major negative
impact on social function and objective quality of life
[6]. Social dysfunction has major economic conse-
quences in both the developed and developing world.
There is evidence that anti-inflammatory treatment may
have beneficial effects in schizophrenia. In preliminary
clinical trials for treatment of schizophrenia, Cox-2 inhibi-
tors have shown favorable effects [1,7]. In our recent
randomized double-blind placebo-controlled clinical trial
in Pakistan and Brazil, the addition of minocycline (an
antibiotic and anti-inflammatory drug) for one year to
treatment as usual (TAU) reduced negative symptoms and
improved some cognitive measures [8].
Statins are primarily HMG-CoA reductase inhibitors but
are also anti-inflammatory agents. Similar to the Cox-2
inhibitors, they have the potential to improve these symp-
toms of schizophrenia [9]. The statins are also known to
decrease C-reactive protein (CRP), which has been shown
in an SMRI-funded study to be elevated in schizophrenia.
Fan et al. [10] demonstrated in patients with schizophrenia
higher levels of CRP (>0.50 mg/dl) to be associated with
marked negative symptoms and higher total positive and
negative syndrome scale (PANSS) scores.
Ondansetron, a selective 5-hydroxytryptamine-3 antag-
onist, is used quite commonly as an antiemetic in cancer
patients [11]. There are several small trials suggesting that
ondansetron, as an adjunct to antipsychotics, is effective in
improving negative symptoms and memory in patients suf-
fering from schizophrenia [12-14]. There is also evidence
that 5HT3 antagonists have some anti-inflammatory effects
through inhibition of TNF-alpha/interlukin-1beta secre-
tions in human monocytes [15].
Preliminary study
We conducted a small, placebo-controlled, rater-blind 12-
week feasibility study adding ondansetron or simvastatinto TAU in 36 patients with chronic schizophrenia
(ClinicalTrails.gov NCT00929955). Statins and ondansetron
are well tolerated and their side effect profiles well under-
stood. The aim of this study was to examine the tolerability
of both compounds and allow estimation of effect sizes to
power a larger trial. Both treatments were well tolerated
and no serious side effects were reported.
Aims
We propose to test the prediction that addition of
ondansetron and/or simvastatin to TAU for patients
with schizophrenia will result in the following outcomes:
 Primary: improvement in negative symptoms
 Secondary:
improvement in positive or other symptoms
improvement in social functioning
improvement in cognitive functions
possible additive effects of ondansetron and
simvastatin added to TAU
Methods/design
Overview
This is a two center, six-month, double-blind placebo-
controlled, factorial design study of ondansetron and/or
simvastatin added to treatment as usual for patients suf-
fering from schizophrenia, schizoaffective disorder, psych-
osis not otherwise specified or schizophreniform disorder.
This will be a 2 × 2 factorial design, with 54 patients in
each cell, giving a total of 216 patients over three years
(Table 1).
The advantage of a factorial design is the effective
sample size for each drug is 108 for each treatment
factor. However, in addition it allows a test of scientific-
ally and clinically interesting possibility that the two
drugs have additive or even multiplicative benefits. A
possible minor disadvantage is that all participants take
two types of pills.
The study will be conducted in Karachi, Pakistan and
San Paulo, Brazil. The patients will be recruited both
from inpatient and outpatient settings. The patients will
be identified and first approached by the treating psychi-
atrists and the multi-disciplinary teams (MDT). The
patients will continue to take treatment as usual during
the trial. While the study assessments will be done by
the research assistants (RAs), the responsible psychiatrist
Table 2 Statistical analysis plan
Placebo Simvastatin Total
Placebo A B (A + B)/2
Ondansetron C D (C + D)/2
Total (A + C)/2 (B + D)/2
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changes to dose or types of medications will be recorded
on monthly reviews.
After consenting to take part in the study, the clinical
symptoms, cognitive, neurological and general level of
function of the participants will be assessed. When these
measures are completed, the patient will be randomized
to one of the four treatment arms. During the course of
the study the patient will also have additional support by
doctors and RA from the research team and continued
support from their mental health care team. If necessary,
members of the research team will be available 24 hours
a day, 7 days a week.
Allocation
In this study patients will be allocated to treatment
group according to a randomized permuted blocks algo-
rithm, after stratification by center. Allocation will be
determined in Manchester by pseudo-random number
generation by the trial statistician. The results will be
conveyed to the trial pharmacist so that medication can
be given to participants without anyone else on the team
being aware of the allocation (that is, double blind).
Power calculation and statistical analysis
Our previous experience with trials in this area [8] and
the pilot lead us to expect 20% dropout across all cells.
In that case, we will have outcomes on 43 participants
within each cell of the design. Assume, for the sake of
illustration, that the mean PANSS negative score in the
cell without either drug is 20 points after six months.
Also assume that the single-drug-only cells (B and C)
both have a mean PANSS negative score of 18 points.
Finally, after treatment with both drugs (D), mean out-
come score is 17 points (that is, a departure from addi-
tivity). The within-cell standard deviation is taken to be
about five units. Using a two-way analysis of variance
with a significance level of 0.05, the trial will have about
45% power to detect departures from additivity of this
size. It will have about 80% power to detect differences
between the cells with and without ondansetron in the
cells without simvastatin (that is, A versus C), and, simi-
larly, the differences with and without simvastatin in the
two cells without ondansetron (A versus B). The follow-
ing is based on the assumption that the two treatment
effects are, indeed, additive (no interaction). When test-
ing the effects of ondansetron, for example, the contrast
will compare the mean of the 86 participants allocated
to receive this drug with the mean of the 86 who were
not (C and D versus A and C), and the trial will have
over 90% power to detect the overall effects based on
this contrast (Table 2).
All analyses will be based, as far as possible, on the
intention-to-treat principle (with weighting adjustmentsto allow for differential loss to follow-up – see below).
Analysis of the three- and six-month quantitative out-
comes will be based on an analysis of covariance
(ANCOVA), using relevant baseline score and center
membership as covariates. In line with the factorial de-
sign, we will initially evaluate the interaction between
ondansetron and simvastatin. If this (as expected) is not
statistically-significant, we will proceed to estimate the
main effects of each of these two drugs separately (that
is, in terms of the 2 × 2 design in the table above, by
comparison of row means for ondansetron and column
means for simvastatin, respectively). If the interaction
was found to be statistically-significant the analysis
would involve the estimation of all of the parameters of
the saturated model. Patterns of missing outcome data
will be examined as a function of recorded baseline
characteristics and patterns of compliance with the treat-
ment protocol. Adjustments will be made to allow for
biases arising from patterns of missing outcome data
linked to protocol violations using inverse-probability
weighting.
Inclusion criteria
1. Patients aged 18 to 65 years
2. Patients will be recruited both from inpatients and
outpatients.
3. Diagnostic and Statistical Manual-IV (DSM-IV TR)
diagnosis of schizophrenia, schizoaffective disorder,
psychosis not otherwise specified or
schizophreniform disorder
4. Competent and willing to give informed consent
5. Stable on medication four weeks prior to baseline
6. No planned medication change
7. Able to take oral medication and likely to complete
the required evaluations
8. Female participants of child bearing age must be
willing to use adequate contraceptives for the
duration of the study and be willing to have a
pregnancy test pre-treatment and at 10 weekly
intervals while on study medication,
9. Not planning to relocate in the next 12 months
Exclusion criteria
1. Relevant International Statistical Classification of
Diseases and Related Health Problems (ICD)-10
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(including ECG conduction abnormalities,
neurological disorder or an active seizure)
2. Subjects who will meet the criteria for a DSM-IV
TR diagnosis of alcohol or substance abuse (other
than for nicotine) within the last month or the
criteria for DSM-IV TR alcohol or substance
dependence (other than for nicotine) within the last
six months
3. Any change of psychotropic medications within the
previous four weeks
4. Pregnant or lactating women and those of
reproductive age without adequate contraception
Interval of assessments
There will be a screening, a randomization and seven
follow-up visits. Full clinical and neurocognitive assess-
ments will be carried out at baseline (randomization), 14
weeks and at 26 weeks, while PANSS, pill count and side
effects checklist will be carried out at every visit. The
clinical interview and ratings will take approximately 50
minutes. The neuropsychological assessments will takeTable 3 Schedule of assessments
Assessment Who
Pt. RA RMO Scr.
Case note review x
SCID x x
Drug treatment history x x
Medical history x x
Physical exam x x
Body weight and BMI x
BP and HR x x
Lab screen x x
Pregnancy screen (urine) x
Inclusion criteria x x
Exclusion criteria x x
Withdrawal criteria x





Social function Scale x
Cognitive assessments x
Antipsychotic side effects x
Side effects simvastatin/ondansetron x x
Compliance monitoring x
(Pt. Patient; RA, Research Assisstant; RMO, Reseident Medical Officer; W2, Wee
Week22; W26, Week26)about 60 to 80 minutes. The patients will primarily be
seen at their treating team’s base. In special circumstances,
if requested by the treating team or patient, the RAs can
visit at home (Table 3).RA training and interrater reliability
Research assistants in Karachi were trained in Structured
Clinical Interview for DSM-IV (SCID), clinical and neuro-
psychological assessments at the University of Manchester
for a previous SMRI funded study. Interrater reliability ses-
sions will be conducted by local PIs, using training videos.Treatments
Treatment as usual
The patients can either be on first or second generation
antipsychotic medications, as deemed suitable by the re-
sponsible psychiatrist. From our experience with previous
study across the two centers in 144 patients, the distribu-
tion was approximately 50:50 between the two generations
of antipsychotics.When
Rand. W 2 W 6 W10 W14 W18 W22 W26
x
x x x x x x x x
x
x x x
x x x x x x x x
x x
x x x x
x x x x x x x
x
x x x x x x x x





x x x x x x x x
x x x x x x x x
x x x x x x x
k2; W6, Week 6; W10, Week10; W14, Week14; W18, Week18; W22,
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Simvastatin will be started at 20 mg OD, this will be
increased to 40 mg after four weeks. The dose range for
hypercholesterolemia is from 10 mg to 80 mg once daily.
We are not concerned with this drug’s performance in
this indication; therefore, we consider 40 mg taken as
one daily dose appropriate for the purposes of this re-
search study. Statins have been used commonly with
psychotropics for many years.
Ondansetron will be administered in an 8 mg dose.
British National Formulary (BNF) specifies an 8 mg once
daily dose. Studies by Akhondzadeh et al. [12] and
Levkovitz et al. [13] have used 8 mg of ondansetron
added to TAU with good tolerability in patients suffering
from schizophrenia. Ondansetron is well tolerated, has
no significant drug interaction reported, is broken down
by cytochrome P450 and has little effect on metabolism
of other drugs. It is often combined with psychotropic
medication. There is no known indication of unexpected
clinically significant interactions.
Outcome variables
Primary clinical outcome variable
Negative symptom severity is defined by the negative
syndrome subscale score on the Positive and Negative
Syndrome Scale, which is the gold standard for compre-
hensively rating symptoms of schizophrenia [16].
Secondary clinical outcome variables
1. Full PANSS and positive syndrome subscale score
[16]
2. Clinical Global Impression
3. Functional outcome:
 Global Assessment of Function (GAF) from DSM-
IV [17]
 Social Functioning Scale (SFS) self-rating in seven
domains [18]
 Quality of Life Scale (QLS) for treatment effects
related to deficit or negative symptoms [19]
Secondary cognitive outcome measures
We will use pencil and paper tests and the Cambridge
Neuropsychological Test Automated Battery (CANTAB);
measuring all seven domains recommended by MATRICS
(NIMH initiative). These domains include speed process-
ing, attention/vigilance, working memory (nonverbal and
verbal), verbal learning, visual learning, reasoning and
problem solving, and social cognitions. We will use the
following tests:
1. IQ: using WAIS Block design
2. Stroop Task, for divided attention and processing
speed3. Coughlan Learning Task (Verbal and Visual)
4. Verbal Fluency (words and categories)
5. CANTAB
 Intra-Extra Dimensional Set Shifting (IED), which
tests rule acquisition and attentional set shifting
 Spatial Working Memory (SWM), which tests
working memory and strategic planning.
 Paired Associates Learning (PAL), which assesses
episodic memory and learning
Side effects
Self-reported antipsychotic side-effects: Antipsychotic
Non-neurological Side-Effects Rating Scale [20].
Safety assessments
Medical history
The primary purpose of screening is to check for inclu-
sion and exclusion criteria. The RAs will arrange for a
doctor to complete checklists for medical history, review
of systems, a physical exam and arrange a blood draw
for hematology and differential white cell count, and for
clinical chemistry to confirm normal renal and liver
function. These assessments will be repeated after six
months in the trial or at the time of withdrawal from the
study.
Physical assessments
Physical assessments will include ECG, Blood pressure,
pulse, height, waist, weight and body mass index (BMI).
Blood investigations
Blood investigations will include full blood count,
erythrocyte sedimentation rate, liver function tests, lipid
profile, urea, electrolytes and C-reactive protein.
Adverse events
An adverse event (AE) is the development of an undesir-
able medical condition or the deterioration of a pre-
existing medical condition following or during exposure
to a pharmaceutical product, whether or not considered
causally related to the product. An undesirable medical
condition can be symptoms (for example, nausea, chest
pain), signs (for example, tachycardia, enlarged liver) or
the abnormal results of an investigation (for example,
laboratory findings, electrocardiogram). In clinical stud-
ies, an AE can include an undesirable medical condition
occurring at any time, including run-in or washout pe-
riods, even if no study treatment has been administered.
The open question “Have you had any health prob-
lems since you were last asked?” will be used to evoke
spontaneous reports of side effects. A self-completed
checklist of adverse events derived from those specified
in the data sheets for ondansetron and simvastatin will
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effects will be evaluated for intensity and seriousness.
Study procedures
Recruitment
The psychiatry consultants responsible for patient care
will be approached and asked if they will allow their pa-
tients to take part in this research study.
In the first instance, the research clinician will approach
the clinical teams to inform them about the research
study, especially with regard to inclusion and exclusion
criteria. The research clinician will establish good working
relationships with the individual clinical teams. They will
be in regular contact either by phone or by visits to deter-
mine, in collaboration with the clinical team, if patients
are suitable to take part in the research study. If patients
meet the entry criteria, are clinically stable, and the con-
sultant psychiatrist and the clinical team agree the patient
could be a possible participant, the consultant will intro-
duce the study to the patient. With the patient’s agree-
ment, the research clinician will visit the patient to
explain the research study verbally and provide them
with the patient information sheet. After the patient has
had time to read and understand the patient information
sheet (at least 24 h) and is willing to take part, a meeting
(visit one) will be set up with the patient in order to obtain
consent for the research and also consent for the research
team to have access to their medical notes.
Screening visit
Confirmation of patient suitability will be carried out at this
point. This will take the form of checking the Inclusion/Ex-
clusion criteria, confirmation of diagnosis, confirmation of
consent and pregnancy testing, if appropriate. The RAs will
arrange for a doctor to complete checklists for medical his-
tory, physical examination and hematological investigations.
Randomization visit
The baseline clinical and neuropsychological measures
will be completed and the patient will be randomized to
one of the four study arms, allocated a unique identifica-
tion number and will commence study drug treatment.
The patient will be given a study information card
explaining that they are in a clinical study and are taking
simvastatin or ondansetron, the telephone numbers of
the senior research clinicians, the clinical trial office and
the name of the local PIs.
In accordance with (International Conference for Har-
monisation) Good Clinical Practice ((ICH)GCP) copies
of all the above will be placed in the patient’s medical
notes along with contact names and telephone numbers.
Follow-up visits The first follow-up visit will be after
two weeks of the randomization to check for safety andtolerability of the treatment initiated. There will be visits
at week 6, 10, 14, 18 and 22. On all these visits the
patients will collect their trial treatment from their treat-
ment centers. The study drugs at the two sites will be
dispensed from the local pharmacy departments. The
research assistants will collect and deliver these to the
patient at a previously agreed upon location. This will
give the opportunity for the research team to closely
monitor the patient’s physical and mental health, side
effects and compliance (by pill count).
Female patients with childbearing capacity taking part
in the clinical trial will have a pregnancy test on a regu-
lar basis. If they should become pregnant during the
course of the study, they will be withdrawn from the
study.
During the course of the study the patient’s individual
consultant and mental health care team will be respon-
sible for their overall care. If any concerns do occur with
regard to the research study, the research team can be
contacted to discuss these concerns 24 h a day 7 days
per week. The patient will have their study card with the
telephone number of the research clinicians and clinical
trial office if they have any concerns or questions.
One of the co-investigators and/or the study doctor
will be available 24 h per day 7 days per week and will
be contacted by the patient or carers or the research cli-
nicians should this be necessary.
26 week, final visit
At this visit all clinical, neuropsychological, physical and
hematological assessments will be completed. Trial
medication will cease.
At all visits the patient’s cumulative clinical drug treat-
ment will be updated from the case notes.
Study coordination
The study will be coordinated by weekly meetings by
local investigators. There will be two weekly tele- or
video-conferences with the chief investigator. We are
also able to use the access grid facility at the University
of Manchester.
Patient safety
The patients’ day-to-day care is the responsibility of the
consultant in charge of the patient. Any study related
safety concerns are the responsibility of the local princi-
pal investigators (P.I.). The P.I.s and the co-investigators
can be contacted at any time via the clinical trials office
or/and through the senior research clinicians.
Patient withdrawal
Patients may be withdrawn from the treatment study for
the following reasons:
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2. At the discretion of the investigator.
3. If any patients suffers a serious adverse event, or
moderate to severe adverse drug reaction.
4. Any patients meet the criteria for insufficient
compliance. This is defined as either taking less than
75% of antipsychotic or trial medication between
assessment points at baseline, 14 and 26 weeks; or
missing trial medications or antipsychotic altogether
for seven days or more at any period.
5. If a patient becomes pregnant.
They may withdraw from the study entirely (that is,
follow-up) at their own request or at the investigator’s
discretion.Ethical and regulatory standards
Local Research Ethics Committee (LREC)
Ethical approval covering all sites was obtained from the
research and ethics committee of the Pakistan Institute
of Learning and Living and was submitted to the funding
body, Stanley Medical Research Institute.Data and Safety Monitoring Board (DSMB)
The DSMB will be constituted according to NIH guide-
lines, for oversight and monitoring of the conduct of
clinical trial. DSMB will meet every six months to ensure
the safety of participants and the validity and integrity of
the data.Declaration of Helsinki
The research study will be performed in accordance with
the guidelines in the Declaration of Helsinki (1974) as
revised in Tokyo (1975), Venice (1983), Hong Kong
(1989), South Africa (1996) and Scotland (2000).
All members of the research team will comply with Inter-
national Conference on Harmonisation/Good Clinical Prac-
tice (ICH/GCP) Guidelines (1996) which are consistent
with principles which have their origin in the Declaration
of Helsinki.Table 4 Timeline
Milestones (months) –3 1 3 4 5
Setting up/ethical approval X X X
Staff recruitment/training X X X
Patient recruitment/11 per month X X
Intervention X X
Data entry X X
Write up and analysisTeam expertise
Six of the investigators have extensive experience in treat-
ment and management of schizophrenia (Chaudhry, Hus-
ain, Hallak, Drake, Kazmi, Rahman and Deakin). Kazmi
and Rahman as local investigators will be important com-
ponents of success in recruitment. All investigators have
been closely involved in setting up the methodology and
software for gathering clinical and research data in
patients with psychosis. Deakin, Chaudhry, Husain, Stir-
ling and Drake will oversee the training of RAs in
recruiting patients and in diagnostic and symptom ratings.
All of the investigators were involved in feasibility study for
this trial. Deakin, Drake and Chaudhry are experts in psy-
chopharmacology. Chaudhry, Husain, Drake and Hallak
have been PIs in a number of multicentre trials funded by
MRC and SMRI in schizophrenia and have much experi-
ence of large-scale treatment studies in psychosis. Drake,
Stirling, Chaudhry, Hallak and Husain have published lon-
gitudinal studies on negative symptoms, cognition and
quality of life. Husain, Chaudhry, Hallak, Kazmi, Rahman,
Stirling and Deakin ran the SMRI trial of minocycline. Stir-
ling is a reader in psychology and has particular expertise
in neuropsychological testing in schizophrenia. Dunn is
internationally known for his work on clinical trial statis-
tical methodology and has published extensively. He has
led the statistical trial design and analysis in many multi-
center clinical trials, including in the treatment of schizo-
phrenia. He has formal links with the Christie Hospital
Clinical Trials Unit.Discussion
Schizophrenia is characterized by disorder of thought, per-
ception, volition, socialization and psychomotor behavior.
During the clinical course of the illness, deterioration is
manifested with increased severity and persistence of nega-
tive and positive symptoms. Standard pharmacological
treatments have little impact on negative symptoms lead-
ing to diminished social and functional outcome. Anti-
inflammatory treatments have been shown to have some
beneficial effects in schizophrenia. Both simvastatin and
ondansetron provide some evidence of a reduction in
symptoms compared to treatment as usual.6 10 16 24 28 30 32 34 36
X X X X
X X X X X X
X X X X X X X
X X X X
Chaudhry et al. Trials 2013, 14:101 Page 8 of 9
http://www.trialsjournal.com/content/14/1/101The preliminary feasibility study adding ondansetron
or simvastatin to TAU in patients with chronic schizo-
phrenia (ClinicalTrails.gov NCT00929955) showed both
treatments were well tolerated and no serious side ef-
fects were reported. Findings are from this randomized
controlled trial of simvastatin and ondansetron added to
TAU may contribute to evidence in the management of
negative symptoms and cognitive deficits in patients
with schizophrenia.
Trial status
The study is active and currently recruiting patients. We
anticipate completing recruitment by the end of 2012
and final assessments completed by June 2013 (Table 4).
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